← Back to Clinical Trials
Recruiting NCT06203249

Microecology and Immunity in Patients With Anti-MDA5 Antibody Positive Dermatomyositis and Interstitial Lung Disease

Trial Parameters

Condition Microbiome
Sponsor Chinese PLA General Hospital
Study Type OBSERVATIONAL
Phase N/A
Enrollment 50
Sex ALL
Min Age 18 Years
Max Age 100 Years
Start Date 2024-01-20
Completion 2025-12-30

Brief Summary

The purpose of this study was to analyze the relationship between the microbial community, host immunity and the presence or absence of concurrent rapidly progressive interstitial lung disease patients with anti-MDA5 antibody positive dermatomyositis.

Eligibility Criteria

Inclusion Criteria: * Patients who meet the diagnostic criteria of dermatomyositis and anti-MDA 5 antibody positive. * Anti-MDA5 antibody positive DM patients with RPILD meet the diagnostic criteria for RPILD. * Must have undergone bronchoalveolar lavage. * Age≥18 years old. * Patients who signed informed consent forms Exclusion Criteria: * Patients who had other connective tissue diseases. * Patients with ILD or RPILD caused by infection, tumors, drugs, biochemistry and other factors. * Pregnant or lactating patients. * The patient also participated in any other clinical trial. * Disagreement for inclusion in this study

Related Trials